Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Varenicline - Oyster Point Pharmaceuticals

Next Previous
Drug Profile

Varenicline - Oyster Point Pharmaceuticals

Alternative Names: OC-01; OC-01 nasal spray; TYRVAYA; TYRVAYA®

Latest Information Update: 16 Jun 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Oyster Point Pharmaceuticals
  • Developer Ji Xing Pharmaceuticals; Oyster Point Pharmaceuticals
  • Class 3-ring heterocyclic compounds; Antivirals; Azabicyclo compounds; Benzazepines; Bridged-ring heterocyclic compounds; Eye disorder therapies; Pyrazines; Quinoxalines; Small molecules; Smoking cessation therapies
  • Mechanism of Action Alpha4 beta2 nicotinic receptor agonists; Virus internalisation inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Dry eyes
  • Phase II Neurotrophic keratopathy
  • Preclinical COVID 2019 infections

Most Recent Events

  • 28 Apr 2023 Oyster Point Pharmaceuticals completes the phase II OLYMPIA trial for Neurotrophic Keratopathy in USA (Intranasal) (NCT04957758)
  • 27 Apr 2023 Ji Xing Pharmaceuticals and Oyster Point Pharmaceuticals complete a phase I trial for Dry eyes in China (Intranasal) (NCT05576415)
  • 04 Apr 2023 Ji Xing Pharmaceuticals and Oyster Point Pharma complete a phase III trial in Dry eyes in China (Intranasal) (NCT05378945)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top